PTX is part of standard-of-care for HER2+ breast cancer patients; nevertheless, the association between HER2 and PTX treatment efficacy remains surprisingly unclear, with controversial results in both in vitro and in vivo preclinical studies [11]. This evidence concerns the gene ERBB2 and breast cancer.